Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain--or tuberculosis meningitis (TBM)--is often deadly, always hard to treat, and a particular threat to young children. It may leave survivors with lifelong brain damage. Now, researchers at Johns Hopkins Medicine report they have used PET scans, a rabbit model and a specially tagged version of the TB drug rifampin to advance physicians' understanding of this disease by showing precisely how little rifampin ever reaches the sites of TB infection in the brain.
"Really precise information has never been easy to come by for how much rifampin gets to any given patient where it's needed," says corresponding author Sanjay Jain, M.D., professor of pediatrics, radiology and international health at the Johns Hopkins University School of Medicine. "We've been able to use technology to find that long-needed information about this very troubling disease."
Jain, along with lead authors Elizabeth Tucker, M.D., assistant professor of anesthesiology and critical care medicine, and Alvaro Ordonez, M.D., research associate, pediatric infectious diseases at the Johns Hopkins University School of Medicine, as well as other Johns Hopkins and University of Maryland colleagues, published their findings Dec. 5 in Science Translational Medicine.
Tuberculosis, which mostly infects the lungs, sickens more than 10 million people around the world each year, causes more than 1 million deaths and costs the global economy billions of dollars, according to the World Health Organization. TBM, caused when Mycobacterium tuberculosis infects brain tissue and the fluid surrounding the brain and spinal cord, is considered the most lethal and disabling form of TB. Children under the age of 5, and those with chronic diseases--notably diabetes and HIV--are mostly likely to develop TBM. Like all TB diseases, TBM is treated with a combination of drugs, including isoniazid, rifampin and pyrazinamide, taken for a year. However, even with treatment, over half of patients die or have significant neurological injury lasting a lifetime, especially young children.
In the new study, Johns Hopkins researchers engineered a version of rifampin with a charged particle--called a positron--attached to the drug ([11C]rifampin) that allowed them to follow its movement throughout the body using PET (positron emission tomography) scans.
Because TBM symptoms are similar among rabbits and humans, the researchers created an experimentally infected colony of rabbits with TBM, injected them with the tagged drug and tracked levels of the tagged [11C]rifampin throughout the rabbits' brains over six weeks. PET scans revealed that after two weeks of treatment, the penetration of [11C]rifampin into TBM brain lesions significantly decreased, from 32 percent to only 11 percent of the levels of the drug noted in the blood. Significantly, they say, the decrease was not reflected in samples of cerebrospinal fluid (CSF) taken from the rabbits, despite that CSF is currently used as a standard proxy for determining drug and infection levels in people.
"Until now, when treating patients, we've relied on a needle biopsy," says Tucker. "We've assumed that what's happening at the tip of the needle at one time point in a sample is what's happening throughout the affected organ." The new results in the rabbit model, she says, suggest that it's not that simple, at least in the animals. The penetration of rifampin varied among TBM lesions even within a single animal, and changed over the course of the long treatment timeline.
The researchers also gave the tagged version of the drug to 10 adult human TB patients already receiving rifampin therapy. The patients were scanned at the Johns Hopkins PET Center in Baltimore, and these studies were performed under Food and Drug Administration guidelines for new PET tracers. One of the patients, a 24-year-old female, had TBM. Similar to the results in rabbits, a PET scan showed that penetration of the drug into the patient's brain lesions was limited to less than 5 percent.
The findings, the researchers say, help advance understanding of why current drug treatments for TBM may not be as effective. And they say the PET approach offers a potential way to optimize the treatment of TBM, to ensure that enough drug is reaching the infected lesions.
"If further research in animals and humans confirms that rifampin and other anti-TB drugs penetrate differently into their brains," says Ordonez, "we foresee that imaging can help us figure out the concentration of drug needed and tailor the dose for individual patients."
The team also expects that the rabbit model of TBM can be used to answer key questions about the disease and its treatment, including what baseline levels of antibiotics are required to penetrate brain lesions more fully.
"We used to think we could just give a drug and patients should get better," says Jain. "Now, we have tools to measure the nuances that make a difference. PET could be used to study other antibiotics and also allow precision medicine approaches in resource-rich settings, such as the U.S. for other serious infections including MRSA (methicillin-resistant Staphylococcus aureus)."
VIDEO: Research Conversations | New Tuberculosis Meningitis Treatment
Other authors on the paper include Brittaney Ritchie, Mariah Klunk, Richa Sharma, Yong Chang, Julian Sanchez-Bautista, Sarah Frey, Martin Lodge, Steven Rowe, Daniel Holt, William Mathews, Robert Dannals, Carlos Pardo-Villamizar and Sujatha Kannan of Johns Hopkins, Beatriz Guglieri-Lopez, Joga Gobburu and Vijay Ivaturi of the University of Maryland, and Charles Peloquin of the University of Florida.
This work was funded by the National Institutes of Health (R01-EB020539, R01-HL131829, R01-HD069562, K12-HD047349), a Stimulating and Advancing ACCM Research (StAAR) grant from the Johns Hopkins Department of Anesthesiology and Critical Care Medicine, and the Johns Hopkins All Children's Foundation Institutional Research Grant Program.
COI: Sanjay Jain received consulting fees from Mediso Medical Imaging Systems, unrelated to this work. No other conflicts of interest were disclosed.
Source: Johns Hopkins Medicine